Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX

Support Care Cancer. 2013 Nov;21(11):2955-6. doi: 10.1007/s00520-013-1944-y. Epub 2013 Aug 23.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Aged
  • Antiemetics / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Aprepitant
  • Benztropine / administration & dosage
  • Camptothecin / adverse effects
  • Camptothecin / analogs & derivatives*
  • Dexamethasone / administration & dosage
  • Drug Combinations
  • Female
  • Fluorouracil / adverse effects
  • Haloperidol / administration & dosage
  • Humans
  • Leucovorin / adverse effects
  • Male
  • Metoclopramide / administration & dosage
  • Morpholines / administration & dosage
  • Nausea / chemically induced
  • Nausea / drug therapy*
  • Organoplatinum Compounds / adverse effects
  • Pancreatic Neoplasms / drug therapy*
  • Vomiting / chemically induced
  • Vomiting / drug therapy*

Substances

  • Antiemetics
  • Drug Combinations
  • Metoclophen
  • Morpholines
  • Organoplatinum Compounds
  • Aprepitant
  • Benztropine
  • Dexamethasone
  • Haloperidol
  • Metoclopramide
  • Leucovorin
  • Fluorouracil
  • Camptothecin

Supplementary concepts

  • FOLFOXIRI protocol